Search
Boston Scientific Corp
BSXAdd to Watchlist
45.650USD
+1.140+2.56%
Market hours 10/22, 14:07（ET）
67.85BMarket Cap
18.99P/E TTM
Boston Scientific Corp (BSX) Revenue Performance
Updated: Jun 30, 2026Last year, Boston Scientific Corp generated 4.64B USD for its biggest-performing segment, Interventional Cardiology Therapies. The United States made the largest contribution, accounting for 12.86B USD last year. For the latest quarter, Boston Scientific Corp reported the revenue of 1.33B USD for the period ending 2026-06-30, which came from the top-performing segment, Interventional Cardiology Therapies. United States contributed the highest revenue, at 3.43B USD.
By Business
Revenue
Proportion
Annual
Annual
Quarterly
Interventional Cardiology Therapies
Electrophysiology
Endoscopy
Urology
Cardiac Rhythm Management
Watchman
Neuromodulation
Peripheral Interventions
Medsurg Watchman
Other
Global Specialty Pharmaceuticles
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Interventional Cardiology Therapies
4.64B(23.11%)
2.65B(14.48%)
2.42B(15.58%)
2.23B(16.26%)
3.04B(25.56%)
2.30B(23.19%)
2.82B(26.43%)
Electrophysiology
3.33B(16.56%)
1.90B(10.43%)
800.00M(5.16%)
585.00M(4.27%)
365.00M(3.07%)
287.00M(2.90%)
329.00M(3.09%)
Endoscopy
2.92B(14.53%)
2.69B(14.71%)
2.48B(16.00%)
2.22B(16.21%)
2.14B(18.01%)
1.78B(17.96%)
1.89B(17.77%)
Urology
2.71B(13.50%)
2.20B(12.05%)
1.96B(12.66%)
1.77B(12.94%)
1.58B(13.32%)
1.29B(12.97%)
1.41B(13.26%)
Cardiac Rhythm Management
2.33B(11.62%)
2.28B(12.48%)
2.22B(14.30%)
2.10B(15.33%)
2.02B(16.98%)
1.70B(17.19%)
1.94B(18.20%)
Watchman
1.96B(9.75%)
1.52B(8.30%)
1.27B(8.21%)
1.02B(7.44%)
--(--)
--(--)
--(--)
Neuromodulation
1.20B(5.97%)
1.11B(6.06%)
976.00M(6.29%)
917.00M(6.69%)
909.00M(7.65%)
761.00M(7.68%)
873.00M(8.19%)
Peripheral Interventions
996.00M(4.96%)
2.41B(13.20%)
2.11B(13.60%)
1.90B(13.86%)
1.82B(15.31%)
1.58B(15.91%)
1.39B(13.06%)
Medsurg Watchman
--(--)
1.52B(8.30%)
1.27B(8.21%)
1.02B(7.44%)
--(--)
--(--)
--(--)
Other
--(--)
--(--)
--(--)
-60.00M(-0.44%)
--(--)
--(--)
--(--)
Global Specialty Pharmaceuticles
--(--)
--(--)
--(--)
--(--)
13.00M(0.11%)
219.00M(2.21%)
--(--)
By Region
Revenue
Proportion
Annual
Annual
Quarterly
United States
EMEA (Europe, Middle East and Africa)
Asia Pacific
Latin America and Canada
Other Foriegn
Medical Devices-United States
Medical Device - OUS
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
United States
12.86B(64.09%)
10.21B(60.96%)
8.43B(59.16%)
7.63B(60.18%)
6.90B(58.05%)
5.51B(55.56%)
6.10B(56.80%)
EMEA (Europe, Middle East and Africa)
3.45B(17.19%)
3.23B(19.27%)
2.86B(20.05%)
2.53B(19.92%)
2.52B(21.18%)
2.10B(21.15%)
2.26B(21.09%)
Asia Pacific
3.08B(15.34%)
2.69B(16.04%)
2.40B(16.85%)
2.12B(16.68%)
2.07B(17.41%)
1.78B(17.97%)
1.90B(17.68%)
Latin America and Canada
678.00M(3.38%)
624.00M(3.73%)
560.00M(3.93%)
469.00M(3.70%)
386.00M(3.25%)
307.00M(3.10%)
395.00M(3.68%)
Other Foriegn
--(--)
--(--)
--(--)
-60.00M(-0.47%)
--(--)
--(--)
--(--)
Medical Devices-United States
--(--)
--(--)
--(--)
--(--)
10.00M(0.08%)
193.00M(1.95%)
70.00M(0.65%)
Medical Device - OUS
--(--)
--(--)
--(--)
--(--)
4.00M(0.03%)
27.00M(0.27%)
11.00M(0.10%)